Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dr Ismail Kola joins UCB

This article was originally published in Scrip

Executive Summary

UCB has appointed Dr Ismail Kola executive vice-president of UCB and president of UCB New Medicines, the company's discovery research through to 'proof of concept' organisation. He will also join UCB's executive committee on November 23rd. Since March 2007, Dr Kola served as senior vice-president of discovery research and early clinical research and experimental medicine and chief scientific officer at Schering-Plough. He has also worked at Merck & Co and Pharmacia.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC005490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel